Glucoraphanin vs Sulforaphane: Which Form Does Your Supplement Formula Actually Need?

01 · The essential relationship

GR, SF and Myrosinase — and Why the Industry Exists in Two Halves

Glucoraphanin (GR) is a glucosinolate that sits in broccoli seeds, stable and inert. Sulforaphane (SF) is the isothiocyanate that the biological literature connects to KEAP1–NRF2 pathway activation. Myrosinase is the enzyme that converts the first into the second.

The reason the supplement industry splits into GR-based and SF-based products is physical chemistry. GR is a water-soluble thioglucoside; it tolerates dry storage, compression and room-temperature shipping. SF is an electrophilic isothiocyanate that degrades in the presence of heat, oxygen, water and alkaline pH. Pure SF at ambient temperature breaks down within days. That instability is why most finished products ship glucoraphanin and rely on conversion to happen later — either inside the consumer’s body or, with stabilisation technology, in a protected matrix.

But conversion is not a single pathway. When myrosinase hydrolyses GR, the unstable intermediate can proceed in two directions: toward sulforaphane (the desired product) or toward sulforaphane nitrile (biologically inactive). A protein called epithiospecifier protein (ESP) promotes the nitrile route^[7]. ESP is more heat-sensitive than myrosinase — it denatures at roughly 60°C, while myrosinase survives to about 70°C — which is why mild heating can increase SF yield from fresh broccoli. For a formulator, the practical consequence is this: the source of your myrosinase matters. Mustard seed and red cabbage enzyme preparations carry minimal ESP activity compared to broccoli’s own endogenous enzyme, and that difference changes the ratio of SF to nitrile in the finished conversion^[8].

One more detail that matters for every calculation in this article: GR (437.5 g/mol) and SF (177.3 g/mol) have different molecular weights. 1 mg of glucoraphanin cannot yield 1 mg of sulforaphane, even at 100% theoretical efficiency. The full arithmetic is in Section 07, but keep it in mind whenever you see a “sulforaphane equivalent” number on a competitor’s label.

02 · Three established routes, one emerging approach

Four Ways to Deliver Sulforaphane from a Broccoli Seed Extract

Routes  ①–③ have multi-year commercial track records and published human data. Route ④ was introduced in September 2026 as a single commercial product; its 27 mg/serving claim comes from company-run UPLC testing and simulated gastric fluid dissolution, not from independent clinical trials^[11]. It is included here as a formulation concept — converting GR outside the body to bypass gastric acid — rather than a validated delivery system. The remainder of this article focuses on the three established routes.

03 · Label strategy

What Are You Actually Claiming on the Supplement Facts Panel?

Before choosing a grade, decide what number goes on the label. This is not a formulation question — it is a regulatory and marketing question that determines everything downstream.

Option A: Declare glucoraphanin content. The label states the amount of GR per serving, measured by HPLC against a reference standard. The consumer receives a precursor, not the active compound. This is straightforward to substantiate: you test the powder, you report what is in it. Most GR-based products on the US market take this approach.

Option B: Declare “sulforaphane” or “sulforaphane potential.” Some labels convert GR milligrams into “sulforaphane equivalent” assuming complete conversion. This is misleading: 1 mg of GR cannot yield 1 mg of SF even at 100% theoretical efficiency (their molecular weights differ — see Section 07), and real conversion efficiencies range from 1% to 40%. A label that prints “30 mg sulforaphane” on a product containing only GR is overstating what the consumer receives by a large and variable margin.

Option C: Declare preformed SF content. A stabilised SF ingredient contains actual sulforaphane, assayed by HPLC or LC-MS. The label number represents what is in the capsule, not what might theoretically form later. This is the only route where the declared SF milligrams correspond directly to the ingredient.

04 · Route ①

GR-Only: Predictable Content, Unpredictable Conversion

The simplest product: a capsule of standardised GR powder with no added enzyme. Stable, inexpensive, easy to manufacture. The problem is what happens after swallowing.

Without plant myrosinase, GR passes intact through the stomach and small intestine and reaches the colon, where gut bacteria with myrosinase-like activity hydrolyse it to SF. A human feeding study (Li et al., Cancer Prevention Research, 2011) gave 200 μmol purified GR to two populations (rural Chinese and urban American volunteers) and measured urinary SF metabolites over 24 hours. Conversion ranged from 1% to 40% of dose, with no demographic predictor — age, sex and body weight did not explain the variation^[5]. The only observed pattern: daytime conversion exceeded nighttime conversion.

A 2024 study (n = 55) connected this variability to specific gut bacteria. Bifidobacterium, Dorea and Ruminococcus torques correlated positively with SF metabolite excretion; Alistipes and Blautia correlated negatively^[6]. The same study was the first to track sulforaphane nitrile (the inactive product) in human plasma, urine and stool, confirming that the ESP-mediated competing pathway operates in vivo, not just in the lab.

A 2015 Johns Hopkins crossover trial added one useful data point for sourcing: GR from broccoli seed supplements was equally bioavailable to GR from broccoli sprout extracts when neither contained active myrosinase — both yielded roughly 10% urinary recovery^[4]. Seed-derived and sprout-derived GR are interchangeable from a bioavailability standpoint in the GR-only route.

What this means for a brand owner: a GR-only capsule delivers a consistent amount of precursor but an inconsistent amount of active compound. A “high converter” and a “low converter” buying the same bottle receive different products.

05 · Route ②

GR + Myrosinase: Five Variables That Determine Whether It Works

Adding exogenous myrosinase to a GR ingredient shifts conversion from the unpredictable colon to the upper GI tract. The strongest direct evidence comes from a single study with internal controls.

The Mastaloudis 2026 benchmark

A randomised, double-blind crossover trial gave 16 healthy adults 50 mg GR from an extract standardised to ≥13% GR. One arm received GR with vitamin C only; the other received GR with mustard-seed myrosinase plus vitamin C. Both were delivered in capsules^[1].

Two points. The 18.6% baseline in this study was higher than the ~10% historical average in other GR-only trials, possibly because the formulation included vitamin C. And the percentages are molar urinary recovery — the fraction of administered GR moles recovered as SF and metabolites in urine — not the fraction that reached every tissue. They are the standard comparison metric in the field, but they are not a direct measurement of what a consumer “absorbs.”

With that benchmark established, here are the five variables that control this route.

Variable 1: Enzyme source and ESP

Mustard-seed myrosinase is the most-used external enzyme in commercial supplements (Avmacol, Life Extension, SulfoMax all use Sinapis alba). Red-cabbage myrosinase is a second option — PhytoVale offers a preparation at ≥220 U/g from Brassica oleracea var. capitata f. rubra. Both sources are preferred over broccoli’s own endogenous enzyme because mustard and red cabbage carry little or no epithiospecifier protein, reducing competition from the nitrile pathway^[7][8]. A transparency note: the published human bioavailability studies cited in this article (Mastaloudis 2026, Fahey 2019) used mustard-seed myrosinase specifically. PhytoVale’s enzyme option is from red cabbage. Both sources share the low-ESP rationale, but no published head-to-head trial compares their in-body conversion performance directly. Formulators should verify SF generation with whichever enzyme source they select. Allergen implication: mustard is listed in EU Regulation 1169/2011 Annex II; red cabbage is not a listed allergen, which can simplify labelling for EU-destined products. For details on enzyme formulation, see Formulating with Myrosinase.

Variable 2: Vitamin C as a myrosinase cofactor

Ascorbic acid accelerates the myrosinase reaction. A 2025 in vitro digestion study found that adding ascorbic acid to a GR + mustard-myrosinase formulation further enhanced SF formation in simulated small-intestinal conditions and improved SF bioavailability across Caco-2 cell monolayers^[2]. Patent literature confirms near-complete GR-to-SF conversion within 30 minutes in the presence of 1 mmol/L ascorbic acid, versus slower conversion without it. Market validation: Life Extension, Thorne and Avmacol all include 100 mg vitamin C in their GR + myrosinase capsules.

Variable 3: Gastric acid

Myrosinase is a protein enzyme. Stomach acid denatures it. A pilot study of enteric-coated GR + myrosinase tablets found a mean conversion of ~36% regardless of whether participants took a proton-pump inhibitor, while uncoated delivery in subjects with high gastric acidity yielded 25.7%^[9]. Nootropics Depot reported that in its own dissolution testing, myrosinase was “largely inactivated” in simulated gastric fluid at pH 1.2^[11]. The practical implication: a standard capsule exposes the enzyme to stomach acid before it can act on GR. Delayed-release or enteric-coated capsules add a modest cost increment relative to the ingredient itself, but that increment buys a measurable improvement in conversion consistency.

Variable 4: Dosage form

Gummies and chewables involve heat, water activity and acidic flavouring — all enemies of enzyme activity. A GR + myrosinase formulation designed around dry capsules or tablets should not be assumed to work in a wet or heated format without finished-product stability testing. Powder sticks that mix into cool water could be viable if enzyme activity and SF generation are verified after reconstitution.

Variable 5: Shelf-life enzyme decay

A GR + myrosinase combination that generates adequate SF on the day of manufacture may not perform the same way 18 months later. Enzyme activity can decline with time, temperature and moisture exposure — enzymes are proteins, and protein denaturation is cumulative. High water activity and temperatures above 25°C accelerate the decay. The question a buyer should ask: is the sulforaphane-generating capacity verified at manufacture only, or also at the end of the stated shelf life? If the supplier can only show release-date conversion data, the product’s real-world performance at the point of consumer purchase is unknown. Request accelerated and real-time stability data for the enzyme component, not just for the GR assay.

06 · Route ③

Preformed Stabilised SF: No Conversion Needed, Different Trade-offs

A preformed SF ingredient delivers the active compound directly. No enzyme, no conversion variability, no dependence on gut bacteria. The trade-off is stability engineering and cost.

Stabilisation technologies

β-Cyclodextrin (β-CD) inclusion complexes are the most common approach in the nutritional supplement space. PhytoVale’s 5% SF grade uses β-CD stabilisation and ships at ambient temperature. A published study showed that HP-β-CD (hydroxypropyl-β-cyclodextrin) inclusion complexes significantly improved SF retention versus unprotected SF^[3]. Note: HP-β-CD and unmodified β-CD are chemically distinct; performance data from one does not transfer directly to the other.

Maltodextrin spray-dried microcapsules are a third published approach. Wu et al. (2014) showed that spray-drying SF with maltodextrin improved encapsulation efficiency and retention compared to unprotected SF^[15]. This route avoids cyclodextrin entirely but introduces its own carrier mass and process parameters.

α-Cyclodextrin (α-CD) complexes are used in pharmaceutical-grade preparations. SFX-01 (Sulforadex) is a synthetic racemic SF stabilised in a 1:1 α-CD complex, currently in clinical development. A 2025 Phase 1 study confirmed safety and tolerability of enteric-coated SFX-01 tablets in healthy men; an earlier α-CD formulation study reported mild stomach upset in 6 of 10 participants^[10]. This is a drug-development programme, not a supplement ingredient, but the stabilisation chemistry is relevant.

pH behaviour: relevant for liquid and beverage formats

SF is relatively stable under acidic conditions but degrades faster at neutral and alkaline pH. This matters for formulators evaluating drinks, sachets or liquid shots: an acidic beverage base (pH 3–4) may be more compatible with preformed SF than a neutral-pH smoothie mix. In all liquid formats, oxygen exposure and temperature during processing and storage compound the degradation risk. Test SF retention in the actual finished matrix, not in the dry powder.

PhytoVale’s concentrated 10% SF grade specifies −4°C storage and requires cold-chain logistics. Higher SF concentration means less powder per serving, but the refrigeration and shipping costs alter the total landed cost per delivered mg of SF. For a deeper look at where SF losses occur in manufacturing, see Sulforaphane Stability in Manufacturing.

Cost per delivered mg SF: the real comparison

Comparing a GR ingredient and a preformed SF ingredient by price per kilogram of powder is meaningless. The unit that matters is cost per milligram of SF the consumer actually receives. For a GR ingredient, that calculation must factor in the molar conversion ratio (0.405), the expected conversion efficiency, and the added cost of enzyme, cofactor and enteric capsule. For a preformed SF ingredient, it includes the carrier dilution factor, cold-chain logistics (if applicable) and the testing cost to verify SF retention at end of shelf life. A preformed SF 5% grade at ambient storage and a GR 13% + enzyme combination may land closer in total cost-per-delivered-mg than their raw powder prices suggest.

The arithmetic for both routes is in Section 07 below.

07 · From target dose to bill of materials

The Molar Arithmetic Most Supplier Articles Get Wrong

GR and SF have different molecular weights. 1 mg of glucoraphanin cannot produce 1 mg of sulforaphane, even at 100% theoretical conversion. Many ingredient articles — and some product labels — ignore this, leading to inflated “sulforaphane equivalent” claims.

Theoretical maximum: 1 mg GR → 177.3 ÷ 437.5 = 0.405 mg SF (at 100% molar conversion, zero losses). This is the ceiling, never reached in practice.

Four measures that are not the same number

A responsible specification distinguishes these clearly:

Worked example: targeting 30 mg SF equivalent daily

30 mg SF is a commonly referenced research-relevant dose (derived from studies using 100–200 μmol SF). The table below shows the raw-material requirements for each route. These are formulation estimates, not guaranteed in-body delivery — the human conversion data in the right column is what the published studies measured, not a manufacturing specification.

Where the assumptions come from: The ~10% figure is the historical average from multiple GR-only human studies without active myrosinase (Fahey 2015 measured 8–10%; Li 2011 reported a 1–40% range with a central tendency near 10%)^[4][5]. The ~35% is a conservative round-down from Mastaloudis 2026’s 39.8% mean with mustard-seed myrosinase^[1], accounting for the fact that commercial capsules may not replicate a controlled clinical setting exactly. Neither number is a specification — they are planning estimates. Actual results depend on formulation, capsule type, enzyme activity and individual consumer biology.

08 · Ingredient qualification

What the COA Should Actually Prove

Two suppliers both offer “broccoli seed extract, 13% glucoraphanin.” Their powders are not necessarily equivalent. A COA that reports only the headline assay leaves the most important questions unanswered.

One more trap: the analytical method itself can destroy what it is measuring. A 2026 study found that conventional high-temperature GC-MS sample injection caused over 60% SF degradation; an optimised protocol reduced that to below 1%^[14]. If a lab uses an unvalidated SF method, the COA under-reports the actual SF content — or, worse, a supplier uses a harsh method to make a low result look like “no SF present” in a GR-only product. Ask which analytical method was used and whether it has been validated specifically for SF.

PhytoVale publishes typical specification data for its GR 13% grade, including heavy-metal limits tested to the stricter GB national standard. Grade-specific COAs with full test methods are available on request.

09 · Decision framework

Choosing Your Route: Start with the Label, Not the Ingredient

Most formulation projects start by choosing an ingredient and then figuring out the label. Reverse that. Start with what you intend to declare on the Supplement Facts panel, then select the route and grade that substantiates it.

10 · FAQ

Frequently Asked Questions

References

References

Human bioavailability

[1] Mastaloudis A et al. (2026). Exogenous myrosinase from mustard seed increases bioavailability of sulforaphane from a glucoraphanin-rich broccoli seed extract in a randomized clinical study. Scientific Reports. n=16, crossover; GR-only 18.6% vs GR+Myr 39.8% urinary recovery. DOI: 10.1038/s41598-026-39389-4

[2] Zhu et al. (2025). Optimization of sulforaphane bioavailability from a glucoraphanin-rich broccoli seed extract in a model of dynamic gastric digestion and absorption by Caco-2 cell monolayers. Food & Function. In vitro digestion + Caco-2 model; AA + MSP enhanced SF bioavailability. DOI: 10.1039/D4FO04561K

[3] Wu H et al. (2010). Preparation and stability investigation of the inclusion complex of sulforaphane with hydroxypropyl-β-cyclodextrin. Carbohydrate Polymers. DOI: 10.1016/j.carbpol.2010.05.020

[4] Fahey JW et al. (2015). Sulforaphane bioavailability from glucoraphanin-rich broccoli: control by active endogenous myrosinase. PLoS ONE. JHU crossover; GR supplements matched broccoli sprouts at ~10% conversion without myrosinase. DOI: 10.1371/journal.pone.0140963

Gut microbiome and individual variation

[5] Li F et al. (2011). Variation of glucosinolate hydrolysis products in vivo: a study on human volunteers consuming broccoli sprout extracts. Cancer Prevention Research. 200 μmol purified GR; conversion 1–40%; no demographic predictor. DOI: 10.1158/1940-6207.CAPR-10-0260

[6] Bouranis JA et al. (2024). Sulforaphane and sulforaphane-nitrile metabolism in humans following broccoli sprout consumption: inter-individual variation, association with gut microbiome composition, and differential bioactivity. Mol Nutr Food Res. n=55; Bifidobacterium/Dorea positively associated; first human SFN-nitrile tracking. DOI: 10.1002/mnfr.202300286

Epithiospecifier protein and conversion chemistry

[7] Matusheski NV et al. (2004). Heating decreases epithiospecifier protein activity and increases sulforaphane formation in broccoli. Phytochemistry. ESP denatured at ~60°C; myrosinase active to ~70°C; SF yield increased with mild heating. DOI: 10.1016/j.phytochem.2004.04.013

[8] Bones AM, Rossiter JT. (2006). The enzymic and chemically induced decomposition of glucosinolates. Phytochemistry. ESP directs myrosinase-catalysed hydrolysis toward nitrile; mustard seed myrosinase avoids ESP interference. DOI: 10.1016/j.phytochem.2006.02.024

Gastric acid and delivery format

[9] Fahey JW et al. (2019). Bioavailability of sulforaphane following ingestion of glucoraphanin-rich broccoli sprout and seed extracts with active myrosinase: a pilot study of the effects of proton pump inhibitor administration. Nutrients. Enteric-coated ~36% conversion; uncoated with high acidity 25.7%. DOI: 10.3390/nu11071489

Stabilised sulforaphane

[10] Clack G et al. (2025). A Phase 1 randomized, placebo-controlled study evaluating the safety, tolerability, and pharmacokinetics of enteric-coated stabilized sulforaphane (SFX-01) in male participants. Adv Ther. α-CD stabilised synthetic SF; Phase 1 safety confirmed. DOI: 10.1007/s12325-024-03018-1

Emerging approaches and market

[11] Nootropics Depot. (2026). SulfoMax launch. Press release, 8 Sep 2026. Pre-converted powder; 27 mg SF/serving by UPLC; company data, not independent clinical trial. PR Newswire

[12] US FDA. GRAS Notice GRN 496 — TrueBroc glucoraphanin from broccoli seeds (water extract). Specific use levels in specific food categories. FDA GRAS database

[13] University of Exeter. PRO-BROC trial (NCT06561893). Effect of L. plantarum probiotic supplementation on broccoli sulforaphane bioavailability. Status: completed (updated Apr 2026); results not yet published. ClinicalTrials.gov

[14] Melini V et al. (2026). Sulforaphane determination by GC-MS analysis: mitigation of thermal degradation and quality evaluation of two broccoli-based supplements. Molecules. >60% SF degradation from high-temperature GC-MS injection; optimised to <1%. DOI: 10.3390/molecules31152598

Stabilisation technology

[15] Wu Y et al. (2014). Stability and encapsulation efficiency of sulforaphane microencapsulated by spray drying. Carbohydrate Polymers. Maltodextrin spray-dried microcapsules improved SF retention vs unprotected SF. DOI: 10.1016/j.carbpol.2013.11.057